(3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester

We are (3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester CAS:131466-61-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester
CAS.NO:131466-61-0
Synonyms:(3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester
(3R)-3-(TERT-BUTYLDIMETHYLSILYLOXY)GLUTARIC ACID 1-((R)-(-)-MANDELIC ACID ESTER)
(3R)-3-(Tert-Butyldimethylsilyloxy)Glutaric Acid -1-((R)-(-)-Mandelic Acid Ester
 
Physical and Chemical Properties:
Molecular Formula C19H28O7Si
Molecular Weight 396.50700
 
Specification:
Appearance:White crystalline powder
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Rosuvastatin calcium(CAS:147098-20-2).

(3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester


Related News: There are however certain APIs that are unknown and so require additional substances that work in conjunction with the API to produce the required effect.(3-cloropropil) dietoxi (metil) silano CAS:13501-76-3 There are however certain APIs that are unknown and so require additional substances that work in conjunction with the API to produce the required effect.6-fluorohexan-1-ol CAS:373-32-0 Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.Sebacato de bis (2,2,6,6-tetrametil-4-piperidilo) CAS:52829-07-9 Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.

Related Products
Product Name
dodecyl prop-2-enoate View Details
(2S)-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]propanoic acid View Details
N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)thio]-2-hydroxy-2-methylpropionamide View Details
3-Bromo-5-fluoro-4-methoxyaniline manufacturer 4-CHLORO-α-(METHYLAMINO)BENZENE ACETIC ACID manufacturer 2-Bromo-5-nitrobenzotrifluoride manufacturer 3-Bromo-2-fluorotoluene manufacturer 3,5-Bis(trifluoromethyl)phenol manufacturer